– Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study – – Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 – – Initial TORREY Study Open-Label […]
Tag: Gossamer Bio
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
– Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 – – Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib – – Statistically Significant Improvements Observed in NT-proBNP and ECHO Measures of Cardiac Structure and Function […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet